Experts urge health regulators to approve ‘turning point’ dementia drugs
As results show 35% slowing in cognitive decline, health leaders say swift decisions crucialWhat impact will the Alzheimer’s drug donanemab have?Health regulators are being urged to rapidly approve two gamechanging dementia drugs in order to ensure mil…